These antibodies perform exceptionally well in the intended applications and have undergone stringent testing and additional validation to ensure monospecificity.
Trial Size Available
Carrier-Free Available
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol |
|---|---|---|
| Western Blot (WB) | 2-4ug/ml | Western Blot Protocol |
This MAb recognizes an intermediate filament protein of 46kDa, identified as cytokeratin 20 (KRT20). KRT20 is abundantly expressed in goblet cells and enterocytes of the gastrointestinal tract. It is a useful marker of pancreatic and colorectal cancer. KRT20 is expressed under normal, hyperplastic and neoplastic conditions.It has been detected in adenocarcinomas of the colon, stomachand biliary tract. Breast carcinomas are generally non-reactive.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies.  All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time